Adalimumab clinical trials
Adalimumab is named as an intervention in 37 current clinical trials in our China, France, Spain, Canada, Italy, UK, Germany, USA, Belgium, Poland, Mexico, Australia, Switzerland, Czechia, Brazil, South Korea, Taiwan, Israel, Ireland, Denmark, Austria, Turkey, Norway, Japan, Netherlands, Portugal and Egypt registers. 19 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is AbbVie (3). The most-studied condition is Rheumatoid Arthritis. The EU clinical trials register (CTIS) separately lists 7 authorised or ongoing trials.
Where Adalimumab is approved
All regulators →Of the three regulators tracked here, the first to approve Adalimumab was the US, on 31 Dec 2002. It is approved in 3 of the 3 regulators tracked here.
- 10 FDA-approved biosimilars, 9 interchangeable: Abrilada, Amjevita, Cyltezo, Hadlima and others
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Adalimumab
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Adalimumab works
All drug targets →- TNF-alpha inhibitor InhibitorTarget: TNF tumor necrosis factorChEMBL only
- COVID-19Phase 3
- PyodermaPhase 3
- SciaticaPhase 3
- Chronic interstitial cystitisPhase 3
- EnthesitisPhase 3
- Enthesitis-related juvenile idiopathic arthritisPhase 3
- Generalized pustular psoriasisPhase 3
- Inflammatory bowel diseasePhase 3
- Intermediate uveitisPhase 3
- Juvenile ankylosing spondylitisPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201580, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 4860, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Adalimumab
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 16 technology appraisals of Adalimumab. 13 are current, and 13 of these recommend it for at least some patients. 3 older appraisals were replaced or withdrawn.
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Adalimumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 42 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EU
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Adalimumab
- ATC code
- L04AB04
- ChEMBL
- CHEMBL1201580
- DrugBank
- DB00051
- CAS number
- 331731-18-1
- FDA UNII
- FYS6T7F842
- Wikidata
- Q348260
- Wikipedia
- Adalimumab
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Adalimumab
37 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Adalimumab in the EU trials register (CTIS)
7 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Adalimumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
Adalimumab across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
42 single-substance products containing Adalimumab on the HPRA medicines list.
- AMGEVITA 20 mg solution for injection in pre-filled syringeAmgen Europe B.V., · EU/1/16/1164/001
- AMGEVITA 20 mg solution for injection in pre-filled syringeAmgen Europe B.V., · EU/1/16/1164/010
- AMGEVITA 40 mg solution for injection in pre-filled penAmgen Europe B.V., · EU/1/16/1164/014- 016
- AMGEVITA 40 mg solution for injection in pre-filled syringeAmgen Europe B.V., · EU/1/16/1164/002-009
- AMGEVITA 40 mg solution for injection in pre-filled syringeAmgen Europe B.V., · EU/1/16/1164/011-013
Supply shortages
- HukyndraGermany (BfArM) · Production problem · 31 Aug 2026 to 20 Jan 2027
- AmsparityGermany (BfArM) · Other reason · 1 Nov 2025 to 31 Dec 2026
Conditions studied with Adalimumab
39 conditionsAll 39 conditions
| Condition (as registered) | Trials |
|---|---|
| Rheumatoid Arthritis | 5 |
| Crohn Disease | 4 |
| Takayasu Arteritis | 3 |
| Ulcerative Colitis | 2 |
| Juvenile Psoriatic Arthritis | 2 |
| Uveitis | 2 |
| Crohn's Disease | 2 |
| Ankylosing Spondylitis | 2 |
| Inflammatory Bowel Diseases | 2 |
| Psoriatic Arthritis | 2 |
| Enthesitis Related Arthritis | 1 |
| Inflamatory Bowel Disease | 1 |
| Crohn Disease (CD) | 1 |
| Behcet Syndrome, Intestinal Type | 1 |
| Tocilizumab | 1 |
| Adalimumab | 1 |
| Treatment | 1 |
| Takayasu Arteritis (TAK) | 1 |
| Arthritis, Rheumatoid | 1 |
| Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease | 1 |
| Chronic Disease | 1 |
| Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis | 1 |
| Healthy Volunteers | 1 |
| Colitis, Ulcerative | 1 |
| Hidradenitis Suppurativa | 1 |
| Psoriasis | 1 |
| Juvenile Idiopathic Arthritis (JIA) | 1 |
| Inflammatory Arthritis | 1 |
| Immune-related Adverse Event | 1 |
| REM Sleep Behavior Disorder | 1 |
| Drug Monitoring | 1 |
| Retinitis Pigmentosa (RP) | 1 |
| Extensive Macular Atrophy With Pseudodrusen (EMAP) | 1 |
| Tuberculous Meningitis | 1 |
| HIV I Infection | 1 |
| Ultrasound Assessment | 1 |
| TNF | 1 |
| Juvenile Idiopathic Arthritis Associated Uveitis | 1 |
| Uveitis, Anterior | 1 |
Sponsors
lead sponsor per trial+ 17 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Adalimumab trials
How many clinical trials are testing Adalimumab?
37 current trials in our China, France, Spain, Canada, Italy, UK, Germany, USA, Belgium, Poland, Mexico, Australia, Switzerland, Czechia, Brazil, South Korea, Taiwan, Israel, Ireland, Denmark, Austria, Turkey, Norway, Japan, Netherlands, Portugal and Egypt registers name Adalimumab as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Adalimumab trials recruiting patients?
Yes. 19 of the 37 trials are recruiting: 7 with sites in China, 3 with sites in France, 2 with sites in Spain, 4 with sites in Canada, 2 with sites in Italy, 1 with sites in UK, 1 with sites in Germany, 1 with sites in USA, 1 with sites in Belgium, 1 with sites in Poland, 1 with sites in Australia, 1 with sites in Switzerland, 1 with sites in Brazil, 1 with sites in South Korea, 1 with sites in Israel and 1 with sites in Turkey. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Adalimumab clinical trials?
AbbVie (3), Eli Lilly and Company (2), Shanghai Zhongshan Hospital (2) and Centre Hospitalier Universitaire de Saint Etienne (2), among 32 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Adalimumab clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Adalimumab licensed in Ireland?
Yes. The HPRA medicines list includes 42 single-substance products containing Adalimumab, for example AMGEVITA 20 mg solution for injection in pre-filled syringe (Amgen Europe B.V.,). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Adalimumab shortage?
The registers we track list 2 entries for Adalimumab: 2 German notices. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Adalimumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Adalimumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Adalimumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.